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ABSTRACT 
Prehypertension is a highly frequent condition associated with an increased cardiovascular risk. 
Endothelial dysfunction is thought to promote development of hypertension and vascular disease, 
however, underlying mechanisms remain to be further determined.  The present study characterises 
for the first time in vivo endothelial repair capacity of early endothelial progenitor cells (EPCs) in 
patients with prehypertension/hypertension and examines its relation with endothelial function.   
Early EPCs were isolated from healthy subjects (HS) and newly diagnosed prehypertensive and 
hypertensive patients (n=52).  In vivo endothelial repair capacity of EPCs was examined by 
transplantation into a nude mouse carotid injury model.  EPC senescence was determined (RT-PCR 
of telomere length). Nitric oxide (NO) and superoxide production of EPCs was measured using 
electron spin resonance (ESR) spectroscopy analysis. CD34+/KDR+ mononuclear cells and 
circulating endothelial microparticles were examined by FACS analysis. Endothelium-dependent 
and -independent vasodilation were determined by high-resolution ultrasound. In vivo endothelial 
repair capacity of EPCs was substantially impaired in prehypertensive/hypertensive patients as 
compared to HS (re-endothelialized area: 15±3*/13±2* vs. 28±3%; P<0.05 vs. HS).  Senescence of 
EPCs in pre/hypertension was substantially increased and NO production was markedly reduced.  
Moreover, reduced endothelial repair capacity of early EPCs was significantly related to an 
accelerated senescence of early EPCs and impaired endothelial function.   
The present study demonstrates for the first time that in vivo endothelial repair capacity of early 
EPCs is reduced in patients with prehypertension and hypertension and is related to EPC 
senescence and impaired endothelial function, and likely represents an early event in the 
development of hypertension.  
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INTRODUCTION 
Prehypertension is a highly frequent condition affecting about 30% of the adult US population and 
has been defined as a systolic blood pressure range between 120-139 mmHg and/or 80-89 mmHg 
diastolic values.1 2 Prehypertension is thought to be a precursor of stage 1 hypertension, a concept 
that has been further supported by the observations of the TROPHY study demonstrating that 
treatment of prehypertension with the angiotensin-receptor blocker Candesartan prevented and 
postponed development of hypertension even 2 years after termination of active treatment.3 
Importantly, prehypertension is associated with a significantly increased cardiovascular risk.4 
Endothelial dysfunction is thought to be critical in the development of vascular disease.5 6 Of note, 
Taddei et al.7 have observed an abnormal endothelium-dependent vasodilation in the offspring of 
patients with essential hypertension, suggesting that endothelial dysfunction may promote the 
development of hypertension. Moreover, Schlaich et al.8 have recently demonstrated that 
individuals with a positive family history of hypertension had an abnormal L-arginine uptake, 
further supporting the concept that an alteration of endothelial function may contribute to the 
development of essential hypertension. 
Notably, recent experimental studies have suggested that endothelial progenitor cells (EPCs)  
promote endothelial integrit.9 10 11 At present, there are in particular two populations of endothelial 
progenitor cells (EPCs) differentiated based on their appearance in culture, i.e. “early” EPCs 
appearing after 4-7 days, similar to those originally described by Asahara et al.12, and “late” EPCs, 
appearing after 14-21 days.13 14 A beneficial effect on endothelial repair after injury has in particular 
been shown for early EPCs.9 10 11 15 16  Early EPCs have also been termed “circulating angiogenic 
cells”, and are thought to exert their effects in particular by paracrine mechanisms.14 17 Furthermore, 
a relation between the number of  in vitro formed colony forming units of early EPCs and 
endothelium-dependent vasodilation has been suggested.18 However, it remains unclear whether in 
vivo endothelial repair capacity of early EPCs is altered in patients with prehypertension or 
hypertension and is related to an abnormal endothelium-dependent vasodilation and senescence. 
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In the present study, we have therefore examined in vivo endothelial repair capacity of early EPCs 
in prehypertensive and hypertensive patients as compared to healthy subjects and analysed the 
relationship with endothelium-dependent vasodilation and senescence. Importantly, patients 
included in the present study had newly diagnosed prehypertension or hypertension as their only 
cardiovascular risk factor. Moreover, early EPC senescence, as detected by telomere length and 
senescence-associated beta-galactosidase (SA-ß-Gal) staining analysis, as well as nitric oxide (NO) 
and superoxide production, as determined by electron spin resonance (ESR) spectroscopy analysis, 
were examined to understand potential mechanisms leading to an altered early EPC in vivo 
endothelial repair capacity.   In addition, EPC numbers and endothelial apoptotic microparticles 
(CD31+/AnnexinV+ particles) were determined by FACS analysis. 
 
METHODS 
Patient Characteristics and Study Protocol:   Written informed consent was obtained from all 
participants, and the study protocol has been approved by the local ethics committee.  130 non-
smoking volunteers, aged between 40 and 70 years old, without known cardiovascular disease or 
ongoing pharmacological therapies were screened.  Healthy subjects were included when they had 
no cardiovascular risk factors, a systolic blood pressure <120 mm Hg and a diastolic blood pressure 
<80 mm Hg (see below).  Patients with prehypertension (systolic blood pressure between 120 and 
139 mm Hg) or hypertension (systolic blood pressure ≥ 140 mm Hg) were included when they had 
no other cardiovascular risk factors.  In particular, subjects with obesity (BMI > 30), 
hypercholesterolemia (LDL > 160 mg/dl or total cholesterol > 240 mg/dl), positive family history 
for cardiovascular disease, diabetes, renal impairment or known cardiovascular disease were 
excluded. Patients with newly diagnosed hypertension were without pharmacological therapy. 
Blood pressure measurements were performed according to the JNC VII/ESC 2007 
recommendations, i.e. all subjects underwent at least three blood pressure measurements in two 
different visits, after 20-30 minutes of rest, and the measurements were spaced by 5-10 minute 
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intervals, on both left and right arm, in sitting and lying position.  Furthermore, all participants 
underwent a 24-hour blood pressure measurement.  Methodological details for the performed 
analyses, i.e. characterisation of early endothelial progenitor cells and endothelial function, are 
provided in the online Data Supplement (please see http://hyper.ahajournals.org). 
 
RESULTS 
Characteristics of Healthy Subjects (HS) and Patients with Prehypertension and 
Hypertension:  The characteristics of HS and patients with prehypertension or hypertension are 
shown in Table 1.  Notably, newly diagnosed prehypertensive and hypertensive patients were 
included in the present study when they did not have other cardiovascular risk factors. Moreover, no 
patients had to be excluded because of white coat effects, since in all enrolled patients the office 
blood pressure values were confirmed by 24-h blood pressure measurements. 
 
Detection of Homing of Early EPCs to Injured Carotid Artery by FACS Analysis:  Previous 
studies have suggested that mesenchymal stem cells have a very limited capacity to reach the 
carotid artery after intravenous injection, i.e. likely a low pulmonary passage.19 In order to examine 
whether the intravenously injected early EPCs home to the injured carotid artery, early EPCs from 
healthy subjects were stained with carboxyfluorescein-diacetate-succinimidyl-ester (CFSC) and 
injected into the tail vein of nude mice with carotid injury (2x105 cells).  fter 24 hours, the injured 
and the corresponding section of the uninjured contralateral carotid artery were homogenized and 
the number of labelled EPCs was quantified by using FACS analysis.  As shown in Figure 1 A, a 
significant homing of labelled early EPCs was observed in the injured, but not in the uninjured 
carotid artery.  To further examine the localisation of labelled early EPCs in the carotid artery, 
confocal laser scanning microscopy was performed.  
 
Detection of Homing of Early EPCs to Injured Carotid Artery by Confocal Laser Scanning 
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Microscopy Analysis: Confocal laser scanning microscopy analysis was used to obtain selective 
images with increasing depth of the carotid arteries. TAMRA-labelled early EPCs (red signal) were 
detected in the endothelial repair zone of the injured carotid artery, but not in the uninjured carotid 
artery after injection into the tail vein of nude mice with carotid injury (Figure 1 B).  Fluorescence-
labelled early EPCs were localized immediately beneath the endothelial layer as indicated by serial 
imaging with increasing depth by using confocal laser scanning microscopy analysis of the re-
endothelialized zone of the carotid artery (Figure 1 B).  
 
In vivo Endothelial Repair Capacity of Early EPCs:   Transplantation of early EPCs from HS 
markedly accelerated endothelial repair (Figure 2 A and 2 B).  Notably, in vivo endothelial repair 
capacity of early EPCs from patients with prehypertension and hypertension was markedly reduced 
as compared to HS (Figure 2 A).  Representative photographs of repaired endothelium 3 days after 
transplantation of early EPCs from the three different study groups are shown in Figure 2 B. The 
number of early EPCs was similar after 4-day culture in the three groups (159±15 x 106/cm2 in 
healthy subjects vs. 179±27 x 106/cm2 in prehypertensives vs. 149±15 x 106/cm2 in hypertensives; 
P=NS).   
 
Endothelium-dependent and Endothelium-independent Vasodilation:  Flow-dependent, 
endothelium-mediated vasodilation (FMD) was markedly reduced in prehypertensive patients as 
compared to HS (FMD: 11.6±0.7% vs. 8.8±0.7%, P=0.01; Figure 2 C).  FMD was further impaired 
in hypertensive patients (6.5±0.5%; P<0.01 vs. prehypertensive; Figure 2 C). There was no 
significant difference in radial artery diameter between the groups (Table 2).  Arterial blood flow 
measurements were performed to determine whether a reduced increase of arterial blood flow 
during reactive hyperemia could explain the impaired flow-dependent, endothelium-mediated 
vasodilation observed in patients with prehypertension or hypertension.  As shown in Table 2, the 
values for arterial blood flow in response to reactive hyperemia in patients with prehypertension or 
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hypertension were not lower as compared to healthy subjects, thereby rather excluding a reduced 
arterial blood flow response under reactive hyperemia as a mechanism that could explain the 
impaired endothelium-dependent vasodilation observed in prehypertensive and hypertensive 
patients.  Moreover, there were no differences in endothelium-independent relaxation of the radial 
artery between the three groups, suggesting a specifically impaired endothelium-dependent 
vasodilation in prehypertensive and hypertensive patients (Table 2). 
 
Relation Between Early EPC in vivo Endothelial Repair Capacity and FMD:  In vivo 
endothelial repair capacity of early EPCs was positively related to FMD (r=0.38, P<0.05; Figure 2 
D), suggesting that impaired early EPC-mediated endothelial repair capacity is related to a reduced 
endothelium-dependent vasodilation.  
 
Early EPC Senescence as Examined by Telomere Length and SA-ß-Gal Staining:   Senescence 
of progenitor cells is a potential cause of altered function. We have therefore analysed markers of 
early EPC senescence in prehypertensive and hypertensive patients as compared to HS.  Notably, a 
significant telomere shortening was observed in early EPCs from prehypertensive patients (HS vs. 
prehypertensive: 11.7±2.1 kb vs. 8.9±0.8 kb; P<0.01) and from hypertensive patients (7.5±1.1 kb; 
P<0.001 vs. HS; Figure 3 A) as compared to HS.  As a second marker of early EPC senescence the 
acidic SA-ß-Gal staining of early EPCs was examined.  SA-ß-Gal positive early EPCs were 
significantly increased in prehypertensive and hypertensive patients as compared to HS (Figure 3 
B).  
Moreover, there was a significant positive relationship between early EPC telomere length and early 
EPC in vivo endothelial repair capacity (r=0.31; P<0.05; Figure 3 C).  Similarly, as evaluated by 
SA-ß-Gal staining, early EPC senescence was inversely related to early EPC in vivo endothelial 
repair capacity (r=-0.30; P<0.05; Figure 3 D), suggesting that impaired early EPC senescence is 
associated with an impaired in vivo endothelial repair capacity of  early EPCs.  Notably, early EPC 
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telomere length was inversely related to systolic blood pressure values (r=0.69; P<0.05; Figure 3 
E). In addition, the analysis of telomerase activity in a subgroup of prehypertensive and 
hypertensive patients revealed a markedly reduced telomerase activity in early EPCs from these 
patients as compared to early EPCs from HS (HS vs. prehypertensive/hypertensive patients: 
24.2±3.4% vs. 15.8±1.9%, n=12; P<0.05).   
 
Early EPC Nitric Oxide (NO) and Superoxide Production:  Early EPC NO production and 
oxidative stress have been suggested to play an important role for EPC repair capacity.  Early EPC 
NO and superoxide production were therefore examined by ESR spectroscopy analysis. NO 
production was significantly reduced in early EPCs from prehypertensive/hypertensive patients as 
compared to HS (474±28 vs. 376±23 pmol/60 min; P=0.01; n=13-18; Figure 4 A). There was no 
significant difference in early EPC superoxide production between prehypertensive/hypertensive 
patients and HS (Figure 4 B). 
 
FACS Analysis of the Number of Circulating CD34+/KDR+ Mononuclear Cells:  We did not 
observe a significant difference in the numbers of circulating CD34/KDR double-positive 
mononuclear cells between newly diagnosed prehypertensive/hypertensive patients and healthy 
subjects (Figure 5 A). 
 
FACS Analysis of Circulating Endothelial Apoptotic Microparticles:  The number of circulating 
endothelial apoptotic microparticles was not significantly different between newly diagnosed 
prehypertensive/hypertensive patients and healthy subjects (Figure 5 B). 
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DISCUSSION 
The present study demonstrates for the first time that in vivo endothelial repair capacity of early 
endothelial progenitor cells is substantially impaired in patients with newly diagnosed 
prehypertension and hypertension as their only cardiovascular risk factor.  Moreover, increased 
senescence of early EPCs as indicated by telomere shortening and increased SA-ß-Gal-staining in 
prehypertensive and hypertensive patients was related to impaired EPC in vivo endothelial repair 
capacity.  In addition, nitric oxide production as determined by ESR spectroscopy was substantially 
reduced in early EPCs derived from prehypertensive and hypertensive patients, providing a further 
potential underlying mechanism leading to reduced endothelial repair capacity of early EPCs in 
these patients.  Importantly, the present study provides the first evidence that reduced in vivo 
endothelial repair capacity of early EPCs is related to impaired endothelium-dependent 
vasodilation.  We did not observe a significant difference in the number of circulating EPCs (as 
assessed by CD34/KDR double positive mononuclear cells) and endothelial apoptotic 
microparticles in prehypertensive and hypertensive patients as compared to healthy subjects.  These 
findings suggest that impaired in vivo endothelial repair capacity of early EPCs related to 
senescence and a reduced endothelium-dependent vasodilation represents an early event in the 
development of hypertension. 
Endothelial dysfunction is thought to promote development of vascular disease and hypertension.5 6 
20 The present study provides novel evidence indicating that the in vivo endothelial repair capacity 
of early EPCs, as determined by transplantation of early EPCs into nude mice with vascular injury, 
is markedly impaired in prehypertensive and hypertensive patients without other cardiovascular risk 
factors.  Moreover, impaired  in vivo endothelial repair capacity of early EPCs was related to 
increased senescence of EPCs and an impaired endothelium-dependent vasodilation, suggesting that 
a reduced in vivo repair capacity of EPCs is an early event in the development of hypertension and 
vascular disease.  Although these findings do not prove a cause and effect relationship, there is 
evidence to suggest that impaired early EPC repair capacity may contribute to endothelial 
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dysfunction.  In a pre-clinical study, Wassmann et al. have observed that infusion of circulating 
early endothelial progenitor cells was able to augment endothelium-dependent vasodilation.21 
Moreover, interventions that augment early EPC function, such as statin therapy or physical 
exercise, are associated with improved endothelial function.22 23 24 In addition, Hill et al have 
reported an inverse relation between the in vitro obtained number of EPC colony-forming units 
from circulating mononuclear cells and the degree of endothelial dysfunction.18 
Importantly, Murasawa et al.25 have recently observed that overexpression of human telomerase 
reverse transcriptase (TERT) in early EPCs increased their migratory activity and postnatal 
neovascularization capacity, suggesting that senescence and telomerase activity are important  
factors regulating EPC function.  In the present study, we have characterized  EPC senescence in 
prehypertensive and hypertensive patients and its relation to EPC endothelial repair capacity.  
Notably, both measurements of telomere length and SA-ß-Gal staining indicated an increased 
senescence of early EPCs from prehypertensive and hypertensive subjects, that was related to an 
impaired in vivo endothelial repair capacity of early EPCs. In addition, our ESR spectroscopy 
measurements revealed a reduced NO bioavailability in EPCs derived from 
prehypertensive/hypertensive patients.  Notably, several recent studies, including work from our 
own group, have indicated that endothelial NO synthase is critical for EPC function, and that early 
EPC endothelial repair capacity is reduced as a consequence of reduced nitric oxide production in 
early EPCs.10 26 Moreover, lack of eNOS has been shown to reduce basal telomerase activity in 
endothelial cells, that was restored by exogenous eNOS or an NO donor, thus suggesting that a 
reduced NO availability may contribute to reduced telomerase activity.27 
Notably, previous studies have indicated that mesenchymal stem cells have a very limited trans-
pulmonary passage to the carotid artery after intravenous injection.19 We have therefore performed 
studies to determine whether human early EPCs can be detected in the injured carotid artery after 
intravenous injection.  After intravenous injection of labelled human early EPCs we could detect by 
both, i.e. FACS-analyses of homogenized carotid arteries as well as by confocal laser scanning 
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microscopy analyses, an increased homing of early EPCs to the injured carotid artery but not to the 
contralateral uninjured carotid artery.  One likely explanation for the observed homing of early 
EPCs in the injured carotid artery after intravenous injection in the present study is that these cells 
are substantially smaller in size as compared to mesenchymal stem cells as studied by Fischer et 
al.19 Indeed, Fischer et al. have recently observed that bone marrow-derived mononuclear cells, 
likely in size more similar to early EPCs, have a 30-fold higher pulmonary passage as detected in 
the carotid artery after intravenous injection as compared to mesenchymal stem cells.19 
Furthermore, our confocal laser scanning microscopy analyses suggested that the injected early 
EPCs can be detected in the subendothelial space of the endothelial repair zone of the injured 
carotid artery, suggesting that these cells promote the endothelial repair process likely in particular 
by paracrine mechanisms.  These observations are in line with a recent study by Schroeter et al.16   
that detected by fluorescence microscopy a subendothelial homing of intravenously injected early 
EPCs, promoting the endothelial repair response in another model of carotid injury.  Moreover, 
these observations are consistent  with a recent study by Sieveking et al. suggesting that early EPCs 
promote the pro-angiogenic effects largely in a paracrine fashion.17 Therefore, the findings of the 
present study in context with previous findings suggest that the stimulation of the in vivo 
endothelial repair response by early EPCs is likely largely mediated by paracrine effects.  
Endothelial damage is likely characterized by an imbalance of endothelial cell growth/repair and the 
loss of endothelial cells, i.e. by apoptosis.28 In the present study we therefore determined the 
number of circulating CD34+/KDR+ and cultured early endothelial progenitor cells as well as the 
number of circulating endothelial apoptotic microparticles.  We did not observe a significantly 
reduced number of cultured early EPCs or CD34+/KDR+ cells as determined by FACS analysis.  
However, an important difference of the present study as compared to previous studies that have 
examined the number of CD34+/KDR+ cells or cultured early EPCs in patients with established 
cardiovascular disease and cardiovascular risk factors, is that in the present study only patients with 
newly diagnosed prehypertension/hypertension without other cardiovascular risk factors or known 
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cardiovascular disease were included.  Notably, if one looks closely at the results of previous 
studies, e.g. by Vasa et al.29, the number of early EPCs (as determined both by number of 
CD34+/KDR+ cells or cultured early EPCs) was not different for patients that had only one 
cardiovascular risk factor as compared to control subjects, but was substantially reduced in patients 
with several cardiovascular risk factors.  Furthermore, in the study by Vasa et al. hypertensive 
patients did not have a lower number of early EPCs as compared to patients without hypertension.29 
In line with these findings are observations from a recent study by Werner et al.,30 that evaluated the 
prognostic value of CD34+/KDR+ cell numbers for the development of cardiovascular events in  
patients with coronary artery disease (CAD).  In a subgroup of 432 CAD patients with arterial 
hypertension, there was no association between the number of CD34+/KDR+ cells and arterial 
hypertension.  Moreover, a recent study by Delva et al.31 examined the number of cultured early 
EPC in 36 patients with essential hypertension and 24 control subjects and did not report a reduced 
number of cultured early EPCs in hypertensive patients.  However, in patients with advanced and 
refractory hypertension, EPC numbers were reduced in a recent study by Oliveras et al.32  Therefore 
the observations of the present study in the context of previous findings are consistent with the 
notion that the dysfunction of early EPC is rather substantially more pronounced and begins earlier 
as compared to a detectable reduction of the number of circulating early EPCs in patients with 
hypertension.  Importantly, the present study provides for the first time evidence that the in vivo re-
endothelialisation capacity of early EPCs is already profoundly reduced in patients with 
prehypertension and is related to impaired endothelium-dependent vasodilation and senescence of 
early EPCs.  Notably,  whereas endothelium-dependent vasodilation was more profoundly reduced 
in patients with hypertension as compared to prehypertension, the endothelial repair capacity of 
early EPCs was already profoundly impaired in prehypertension, that is in line with the above 
notion, that the functional impairment of early EPCs is likely an early event in the development of 
hypertension. 
In the present study, no increase of circulating endothelial apoptotic microparticles was observed in 
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prehypertensive or hypertensive patients. Notably, Preston et al.33 have observed an increased 
number of circulating endothelial apoptotic microparticles in severely hypertensive patients.  
Werner et al. have recently reported a relation between endothelial dysfunction and the degree of 
endothelial cell apoptosis, as measured by circulating CD31/Annexin V positive endothelial 
apoptotic microparticles in patients with established coronary disease.34  Therefore, the results of 
the present study together with previous observations suggest that a detectable increase of 
circulating endothelial apoptotic microparticles is likely occurring in a more advanced stage of 
hypertension or in patients with established cardiovascular disease.  
 
Limitations of the study:   Different methods are in use to isolate and culture endothelial progenitor 
cells.14 At least two populations have been commonly differentiated, i.e. “early” endothelial 
progenitor cells and “late” outgrowth EPCs obtained after several weeks of culture as pointed out 
recently.13,17  We have examined in the present study the endothelial repair capacity of early EPCs.  
Given that early EPCs are rather more frequent in number, they may play a particularly important 
role for the stimulation of endothelial repair processes.  Furthermore, due to a substantial variation 
in the FACS-determined number of CD34+/KDR+ cells and with respect to the group sizes of the 
present study, conclusions with respect to the numbers of EPCs as determined by FACS analysis 
need to be interpreted with caution.  Given that there was, however, rather a trend for increased 
numbers of CD34+/KDR+ cells in prehypertension/hypertension, the present data suggest that the 
number of these cells is likely not reduced in newly diagnosed prehypertensive/hypertensive 
patients without other cardiovascular risk factors or known cardiovascular disease, and that the 
functional impairment of early EPCs with respect to their endothelial repair capacity is likely 
substantially more pronounced in this early stage of the disease.  
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PERSPECTIVES 
Endothelial dysfunction is thought to contribute to development of hypertension and atherosclerotic 
vascular disease, however, the underlying mechanisms are incompletely understood.  The present 
study provides novel evidence suggesting that in vivo endothelial repair capacity of early 
endothelial progenitor cells (EPCs), likely largely mediated by paracrine effects, is markedly 
reduced in patients with prehypertension and hypertension, and is related to the impairment of 
endothelial function.  These findings indicate that an impaired endothelial repair capacity of EPCs 
is an early event in the development of hypertension and vascular disease and raise the possibility 
that interventions to preserve endothelial repair capacity of EPCs, e.g. by inhibition of their 
accelerated senescence and reduced NO availability, may represent an attractive novel approach to 
stimulate endogenous endothelial repair responses and potentially to prevent endothelial 
dysfunction and development and progression of vascular disease. 
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FIGURE LEGENDS 
 
Figure 1. Detection of homing of early EPCs to the injured and uninjured carotid arteries. A.  
Early EPCs (2 x 105 cells) from healthy subjects were stained with carboxyfluorescein-diacetate-
succinimidyl-ester(CFSC) and injected into the tail vein of nude mice with carotid injury.  After 24 
hours, the injured and the corresponding section of the contralateral uninjured carotid artery were 
homogenized and the number of labelled EPCs was quantified by using FACS analysis (n=3).  B. 
Confocal laser scanning microscopy analysis (magnification x200) of the injured and uninjured 
carotid arteries.  TAMRA-labelled early EPCs (red-signal) were injected into the tail vein of nude 
mice with carotid injury. Confocal laser scanning microscopy analysis was used to obtain selective 
images with increasing depth.  First, the endothelial layer was visualized by whole mount CD31 
immunostaining (green) of the uninjured (I) and injured (II, endothelial repair zone) carotid artery, 
and DAPI staining (mounting media) was used for nuclei staining (blue).  Fluorescence-labelled 
early EPCs (TAMRA; red signal) were located beneath the endothelial layer as indicated by 
repeated serial imaging with increasing depth by confocal laser scanning microscopy analysis of the 
re-endothelialized zone of the carotid artery (III, IV).  In the subendothelial layer of the endothelial 
repair zone of the carotid artery fluorescence-labelled early EPCs (red signal) were clearly 
detectable (V). 
 
Figure 2. In vivo endothelial repair capacity of early EPCs and its relation to endothelium-
dependent vasodilation.  A. Assessment of in vivo endothelial repair capacity of early EPCs, 
expressed as the percentage of re-endothelialization on the denuded area, in mice models of carotid 
injury, after i.v. transplantation of early EPCs derived from healthy subjects, prehypertensive and 
hypertensive patients. B. Representative photographs of mice carotids after injury and  
transplantation of PBS (negative control), early EPCs from healthy, prehypertensive and 
hypertensive subjects. Denuded-endothelium area is stained in blue; re-endothelialized area (REA) 
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in white. C. Flow-dependent, endothelium-mediated vasodilation (FMD), expressed as the 
percentage change of the radial artery diameter.  D. Relation between early EPC in vivo endothelial 
repair capacity and endothelial function, expressed as the percentage change in radial artery 
diameter (r=0.38; P<0.05).   
 
Figure 3.  Senescence of early EPCs and its relation to in vivo endothelial repair capacity and 
systolic blood pressure.  A. Measurement of telomere length in early EPCs derived from healthy 
subjects, prehypertensive and hypertensive patients. B. SA-ß-Gal staining in early EPCs, expressed 
as the mean percentage of SA-ß-Gal positive cells in three random fields. C. Relation between early 
EPC telomere length and early EPC in vivo endothelial repair capacity.  D. Relation between SA-ß-
Gal positive early EPCs and their in vivo endothelial repair capacity.  E. Relation between early 
EPC telomere length and systolic blood pressure. 
 
Figure 4. Electron Spin Resonance (ESR) Spectroscopy of Nitric Oxide Availability and 
Oxidant Stress in Early EPCs.  A. ESR Spectroscopy Analyses of NO production of early EPC in 
healthy subjects and prehypertensive/hypertensive patients; representative ESR spectra of early 
EPC NO production for each group are included (n=13-18). B. ESR Spectroscopy Analyses of early 
EPC Superoxide production in healthy subjects and prehypertensive/hypertensive patients (n=13-
18).  
 
Figure 5.  FACS Analysis of CD34+/KDR+ Cell Number and Apoptotic Endothelial 
Microparticles.  A. Percentage of circulating CD34+/KDR+ mononuclear cells in healthy, 
prehypertensive and hypertensive subjects. B. CD31+/Annexin V+ circulating apoptotic endothelial 
microparticles. 
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Table 1. Characteristics of the Study Population.  
Clinical 
Parameters 
Healthy 
(n=16) 
Prehypertensive 
(n=16) 
Hypertensive 
(n=20) 
P-Value 
 
Age 
 
 
53±2 
 
 
57±3 
 
 
58±2 
 
 
NS 
 
 
Sex   
[M/F] 
 
7/9 
 
 
10/6 
 
 
12/8 
 
 
NS 
 
 
BMI   
[kg/m2] 
 
25±0.7 
 
 
24±0.8 
 
 
26±0.5* 
 
 
*P<0.05 vs. prehyp. 
 
 
Systolic BP 
 [mmHg] 
 
112±2 
 
 
129±2† 
 
 
155±4* 
 
*P<0.05 vs. prehyp. 
†P<0.05 vs. healthy 
 
 
Diastolic BP  
[mmHg] 
 
72±2 
 
 
82±2† 
 
 
93±2* 
 
*P<0.05 vs. prehyp. 
†P<0.05 vs. healthy 
 
 
24h Systolic BP 
[average; mmHg] 
 
116±1 
 
 
129±1† 
 
 
146±3* 
 
*P<0.05 vs. prehyp. 
†P<0.05 vs. healthy 
 
24h Diastolic BP 
[average; mmHg] 
 
73±1 
 
 
81±1† 
 
 
93±3* 
 
*P<0.05 vs. prehyp. 
†P<0.05 vs. healthy 
 
 
Fasting Glucose 
[mg/dl] 
 
89±1.5 
 
 
89±1.5 
 
 
92±2.5 
 
 
NS 
 
 
HbA1c  
[%] 
 
5.6±0.1 
 
 
5.7±0.1 
 
 
5.7±0.1 
 
 
NS 
 
 
LDL Cholesterol 
[mg/dl] 
 
124±7 
 
 
126±4 
 
 
127±6 
 
 
NS 
 
 
HDL Cholesterol 
[mg/dl] 
 
70±3 
 
 
73±4 
 
 
68±4 
 
 
NS 
 
 
Creatinin 
[mg/dl] 
 
 
0.9±0.03 
 
 
0.9±0.07 
 
 
0.9±0.02 
 
 
NS 
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Table 2. Radial Artery Diameter and Blood Flow at Baseline and during Reactive Hyperemia 
in Healthy Subjects, Prehypertensive and Hypertensive Patients. 
Endothelium-dependent and  
–independent  vasodilation 
Healthy Prehypertensive Hypertensive P-Value 
 
Diameter, mm 
Baseline 
 
Increase under reactive 
hyperemia, FMD % 
 
Increase 
after Nitroglycerin, % 
 
 
2.73±0.1 
 
11.6±0.7 
 
25.9±2.6 
 
 
 
 
2.78±0.1 
 
8.8±0.7* 
 
21.9±3.3 
 
 
 
2.99±0.1 
 
6.5±0.5* 
 
21.2±1.5 
 
 
 
 
NS 
 
 
 
P<0.05 vs. 
Healthy 
 
NS 
 
 
 
 
Blood Flow, mL/min 
Baseline 
 
Reactive hyperemia 
 
 
30.6±3.6 
 
105±4 
 
 
 
32.7±2.6 
 
146±15 
 
 
 
37.4±3.0 
 
126±17 
 
 
NS 
 
NS 
 
FMD: Flow-dependent, endothelium-mediated vasodilation. 
 
